The primary objectives of this study are to compare LY2835219 plus Best Supportive Care (BSC) versus erlotinib plus BSC in patients with Stage IV NSCLC whose tumors have detectable KRAS mutations by an assay done at a central laboratory and who have progressed after prior platinum-based therapy and one other prior therapy or are not eligible for further chemotherapy with respect to progression free survival and overall survival.
- Stage IV NSCLC
- KRAS mutation as confirmed by Central Lab
- Have progressed on a platinum based chemotherapy and one other prior chemotherapy or is judged not eligible by physician for further standard second-line chemotherapy
- Have measurable disease
- Has discontinued all previous treatment for a least 21 days for myelosuppressive agents or 14 for nonmyelosuppressive agents